Several global reinsurers have pulled back from US healthcare lines, creating room for specialists focused on stability, underwriting depth, and long-term commitment.
Commercial group medical costs are projected ↑~9% in 2026, making technical expertise more important as clients evaluate durable reinsurance partnerships and pricing clarity.
Employer health insurance costs are projected ↑~7% in 2026, with pharmacy inflation driven by GLP-1s, specialty drugs, and cell therapies leading the pressure.
Provider groups taking financial risk, plus oncology, nephrology, cell and gene therapy, and behavioral health, are driving demand for tailored structures now.
Cedants still favor firm renewal pricing, but partners offering underwriting clarity, tailored structures, and multi-yr stability are positioned to stand out now.
